Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like A*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000077	AbbVie	03/31/2022	00074081702	(adalimumab) HUMIRA 10MG/0.1ML PFS 2-PACK	01/14/2022	441.65	6409.83	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074006702	(adalimumab) HUMIRA 1X80MG,0.8ML, 1X40MG,0.4ML PFS2PKPED CROHN'S STARTER PACK	01/14/2022	662.47	9614.78	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074061602	(adalimumab) HUMIRA 20MG/0.2ML PFS 2-PACK	01/14/2022	441.65	6409.83	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074433902	(adalimumab) HUMIRA 40MG/0.8 ML (2 PENS)	01/14/2022	441.65	6409.83	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074379902	(adalimumab) HUMIRA 40MG/0.8ML (2 SYRINGES)	01/14/2022	441.65	6409.83	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074254003	(adalimumab) HUMIRA 80MG, 0.8ML PFS 3-PACKPED CROHN'S STARTER PACK	01/14/2022	1324.95	19229.57	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074012403	(adalimumab) HUMIRA CROHN'S 80MG/0.8ML, 3 PENS STARTER PACK	01/14/2022	1324.95	19229.57	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074055402	(adalimumab) HUMIRA PEN, 40MG/0.4ML, 2 PENS	01/14/2022	441.65	6409.83	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074024302	(adalimumab) HUMIRA PFS, 40MG/0.4ML, 2 SYRINGES	01/14/2022	441.65	6409.83	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074153903	(adalimumab) HUMIRA PSORIASIS; 1X80MG, 2X40MG (3PENS) STARTER PACK	01/14/2022	883.29	12819.69	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074433906	(adalimumab) HUMIRA, CROHN'S, 40MG/0.8 ML (6 PENS) STARTER PACK	01/14/2022	1324.95	19229.57	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074433907	(adalimumab) HUMIRA, PSORIASIS, 40MG/0.8ML (4 PENS) STARTER PACK	01/14/2022	883.29	12819.69	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074003828	(elagolix sodium) ORILISSA 150MG TABS, 4X7 PACK	01/14/2022	72.12	1046.66	09/01/2036	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074003956	(elagolix sodium) ORILISSA 200MG TABS, 4X14 PACK	01/14/2022	72.12	1046.66	09/10/2024	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074244003	(leuprolide acetate) LUPRON DEPOT PED, 15 MG PDS KIT	01/14/2022	174.82	3742.62	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074377903	(leuprolide acetate) LUPRON DEPOT PED, 3MONTH, 11.25MG	01/14/2022	476.18	10194.21	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074969403	(leuprolide acetate) LUPRON DEPOT PED, 3MONTH, 30MG	01/14/2022	524.47	11227.90	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074210803	(leuprolide acetate) LUPRON DEPOT PED, 7.5 MG PDS KIT	01/14/2022	87.43	1871.71	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074366303	(leuprolide acetate) LUPRON DEPOT, GYN,3 MONTH 11.25 MG PDS KIT	01/14/2022	218.03	4667.64	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074364103	(leuprolide acetate) LUPRON DEPOT, GYN,3.75 MG PDS KIT	01/14/2022	72.68	1555.87	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074334603	(leuprolide acetate) LUPRON DEPOT, URO,3 MONTH 22.5 MG PDS KIT	01/14/2022	259.81	5562.15	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074368303	(leuprolide acetate) LUPRON DEPOT, URO,4 MONTH 30 MG PDS KIT	01/14/2022	346.42	7416.22	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074364203	(leuprolide acetate) LUPRON DEPOT, URO,7.5 MG PDS KIT	01/14/2022	86.61	1854.06	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074228203	(leuprolide acetate) LUPRON DEPOT-PED 11.25 MG PDS KIT	01/14/2022	158.73	3398.06	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074347303	(leuprolide acetate) LUPRON, URO,45MG 6MTH	01/14/2022	519.64	11124.49	02/05/2031	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032121201	(lipase/protease/amylase) CREON 12000USP DELAYED-RELEASE 100CAP	01/14/2022	21.99	376.72	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032121207	(lipase/protease/amylase) CREON 12000USP DELAYED-RELEASE 250CAP	01/14/2022	54.98	941.79	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032122401	(lipase/protease/amylase) CREON 24000USP DELAYED-RELEASE 100CAP	01/14/2022	43.60	746.73	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032122407	(lipase/protease/amylase) CREON 24000USP DELAYED-RELEASE 250CAP	01/14/2022	107.23	1836.75	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032120370	(lipase/protease/amylase) CREON 3000USP DELAYED-RELEASE 70CAP	01/14/2022	6.50	111.43	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032301613	(lipase/protease/amylase) CREON 36000USP DELAYED-RELEASE 100CAP	01/14/2022	66.20	1133.82	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032301628	(lipase/protease/amylase) CREON 36000USP DELAYED-RELEASE 250CAP	01/14/2022	165.46	2834.20	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032120601	(lipase/protease/amylase) CREON 6000USP DELAYED-RELEASE 100CAP	01/14/2022	11.00	188.47	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00032120607	(lipase/protease/amylase) CREON 6000USP DELAYED-RELEASE 250CAP	01/14/2022	27.51	471.22	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2022	00074204202	(risankizumab-rzaa) SKYRIZI 75MG/0.83ML PFS x2 US/PR	01/14/2022	1259.02	18272.79	02/04/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074057634	(venetoclax) VENCLEXTA 100MG BOTTLE 180 TABLETS*	07/05/2022	505.84	20739.36	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074057622	(venetoclax) VENCLEXTA 100MG BOTTLE, 120 TABLETS*	07/05/2022	337.23	13826.24	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074057611	(venetoclax) VENCLEXTA 100MG UNIT DOSE, 1 TABLET*	07/05/2022	2.81	115.21	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074056111	(venetoclax) VENCLEXTA 10MG UNIT DOSE, 2 TABLETS*	07/05/2022	0.56	23.04	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074056114	(venetoclax) VENCLEXTA 10MG WALLET, 2 TABLETS X 7*	07/05/2022	3.93	161.30	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074056611	(venetoclax) VENCLEXTA 50MG UNIT DOSE, 1 TABLET*	07/05/2022	1.41	57.61	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074056607	(venetoclax) VENCLEXTA 50MG WALLET, 1 TABLET X 7*	07/05/2022	9.84	403.27	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	09/30/2022	00074057928	(venetoclax) VENCLEXTA START PACK, 4X7 DAY WALLET*	07/05/2022	72.78	2984.16	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000018	ACADIA Pharmaceuticals Inc.	03/31/2022	63090010030	Nuplazid Oral Tablet 10mg - 30 each	02/05/2022	193.00	4173.00	04/29/2030	Single Source Drug	None	1	ACADIA prices our medicines to reflect their value to patients, payers and society. Our goals are to reduce the burden of disease and deliver better health outcomes with our therapies.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000018	ACADIA Pharmaceuticals Inc.	09/30/2022	63090010030	Nuplazid Oral Tablet 10mg, 30 tablets	08/23/2022	392.00	4565.00	08/27/2038	Single Source Drug	None	1	ACADIA prices our medicines to reflect their value to patients, payers and society. Our goals are to reduce the burden of disease and deliver better health outcomes with our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000018	ACADIA Pharmaceuticals Inc.	03/31/2022	63090034030	Nuplazid Oral Tablet 34mg - 30 each	02/05/2022	193.00	4173.00	04/29/2030	Single Source Drug	None	1	ACADIA prices our medicines to reflect their value to patients, payers and society. Our goals are to reduce the burden of disease and deliver better health outcomes with our therapies.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000018	ACADIA Pharmaceuticals Inc.	09/30/2022	63090034030	Nuplazid Oral Tablet 34mg, 30 tablets	08/23/2022	392.00	4565.00	08/27/2038	Single Source Drug	None	1	ACADIA prices our medicines to reflect their value to patients, payers and society. Our goals are to reduce the burden of disease and deliver better health outcomes with our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000278	Acella Pharamceuticals, LLC	03/31/2022	42192071401	Ciclopirox Treatment External Kit 8%, solution, 34.6 ML, unit of size 1 box	01/17/2022	46.91	362.91	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Drug not acquired within the past five years
Rx0000278	Acella Pharamceuticals, LLC	03/31/2022	42192060840	Gabapentin 300mg/6ml US 40	01/17/2022	12.38	137.38	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	columns were left blank because this product was not acquired from another manufacturer in the last five years.
Rx0000454	AcelRx Pharmaceuticals, Inc.	12/31/2022	61621043001	Dsuvia Sublingual Tablet Sublingual 30 MCG	10/01/2022	9.61	73.73	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000454	AcelRx Pharmaceuticals, Inc.	12/31/2022	61621043011	Dsuvia Sublingual Tablet Sublingual 30 MCG, 10 Each, Unit-Dose, Box	10/01/2022	96.17	737.32	07/29/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000157	Acrotech Biopharma LLC	12/31/2022	48818000101	Folotyn (Pralatrexate) IV Inj 20 MG/ML, 1 ML, Unit-Dose, Vial	10/04/2022	257.20	6687.21	05/31/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000157	Acrotech Biopharma LLC	12/31/2022	48818000102	Folotyn (Pralatrexate) IV Inj 40 MG/2ML, 2 ML, Unit-Dose, Vial	10/04/2022	514.40	13374.42	05/31/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215061006	UPTRAVI® (selexipag) Strength:1000 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215061206	UPTRAVI® (selexipag) Strength:1200 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215061406	UPTRAVI® (selexipag) Strength:1400 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215061606	UPTRAVI® (selexipag) Strength:1600 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215060214	UPTRAVI® (selexipag) Strength:200 mcg Package Size:140 Form:Tablet	09/15/2022	1308.11	31729.30	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215060206	UPTRAVI® (selexipag) Strength:200 mcg Package Size:60 Form:Tablet	09/15/2022	560.62	13598.27	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215062820	UPTRAVI® (selexipag) Strength:200+800 mcg Package Size:200 Form:Tablet	09/15/2022	1308.10	31729.05	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215060406	UPTRAVI® (selexipag) Strength:400 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215060606	UPTRAVI® (selexipag) Strength:600 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000251	Actelion Pharmaceuticals US, Inc	09/30/2022	66215060806	UPTRAVI® (selexipag) Strength:800 mcg Package Size:60 Form:Tablet	09/15/2022	871.85	21147.54	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of October 4, 2022.
Rx0000328	Adamas Pharmaceuticals, Inc.	09/30/2022	70482017060	Gocovri Oral Capsule Extended Release 24 Hour 137 MG, 60 Each, Bottle	07/01/2022	142.54	2993.29	08/23/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000328	Adamas Pharmaceuticals, Inc.	09/30/2022	70482008560	Gocovri Oral Capsule Extended Release 24 Hour 68.5 MG, 60 Each, Bottle	07/01/2022	142.54	2993.29	08/23/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2022	76431011001	JUXTAPID 10 MG CAPS, bottle of 28 capsules	01/01/2022	1395.06	47897.18	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2022	76431012001	JUXTAPID 20 MG CAPS, bottle of 28 capsules	01/01/2022	1395.06	47897.18	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2022	76431013001	JUXTAPID 30 MG CAPS, bottle of 28 capsules	01/01/2022	1395.06	47897.18	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2022	76431010501	JUXTAPID 5 MG CAPS - bottle of 28	01/01/2022	1395.06	47897.18	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2022	76431021001	MYALEPT 11.3MG VIAL	01/01/2022	238.37	5535.42	12/31/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000477	Agile Therapeutics	09/30/2022	71671010003	Twirla Transdermal Patch Weekly 120-30 MCG/24HR, 1 Each, Unit-of-Use, Box Qty 3	07/15/2022	16.43	191.20	08/26/2028	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000477	Agile Therapeutics	09/30/2022	71671010011	Twirla Transdermal Patch Weekly 120-30 MCG/24HR, 1 Each, Unit-of-Use, Package	07/15/2022	5.47	63.73	08/26/2028	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000400	AkaRx, Inc., a Sobi company	09/30/2022	71369002010	DOPTELET, 1 BLISTER PACK in 1 CARTON > 10 TABLET, EQ 20MG BASE	07/01/2022	244.20	3733.40	05/05/2025	Single Source Drug	None	1	AkaRx (and its affiliated companies) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to: a) the clinical value of the medicine; b) the economic value of the medicine; c) market dynamics and competitor pricing; d) discounts provided to customers in the public and private sectors; and e) patient support provided by AkaRx to ensure patient access.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000400	AkaRx, Inc., a Sobi company	09/30/2022	71369002015	DOPTELET, 1 BLISTER PACK in 1 CARTON > 15 TABLET, EQ 20MG BASE	07/01/2022	366.30	5600.10	05/05/2025	Single Source Drug	None	1	AkaRx (and its affiliated companies) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to: a) the clinical value of the medicine; b) the economic value of the medicine; c) market dynamics and competitor pricing; d) discounts provided to customers in the public and private sectors; and e) patient support provided by AkaRx to ensure patient access.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000400	AkaRx, Inc., a Sobi company	09/30/2022	71369002030	DOPTELET, 2 BLISTER PACK in 1 CARTON > 15 TABLET, EQ 20MG BASE	07/01/2022	732.60	11200.20	05/05/2025	Single Source Drug	None	1	AkaRx (and its affiliated companies) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to: a) the clinical value of the medicine; b) the economic value of the medicine; c) market dynamics and competitor pricing; d) discounts provided to customers in the public and private sectors; and e) patient support provided by AkaRx to ensure patient access.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000417	Akebia Therapeutics, Inc.	03/31/2022	59922063101	AURYXIA (ferric citrate) 210 mg Tablets: Bottle of 200	01/19/2022	84.00	1364.00	07/21/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Auryxia was developed by Keryx Biopharmaceuticals. In December 2018, Keryx Biopharmaceuticals and Akebia Therapeutics merged. Keryx Biopharmaceuticals is now a wholly owned subsidiary of Akebia Therapeutics. Auryxia is not an acquired product based on this history.
Rx0000417	Akebia Therapeutics, Inc.	06/30/2022	59922063101	AURYXIA (ferric citrate) 210 mg Tablets: Bottle of 200	04/15/2022	30.00	1394.00	07/21/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Auryxia was developed by Keryx Biopharmaceuticals. In December 2018, Keryx Biopharmaceuticals and Akebia Therapeutics merged. Keryx Biopharmaceuticals is now a wholly owned subsidiary of Akebia Therapeutics. Auryxia is not an acquired product based on this history.
Rx0000085	Akorn Inc	12/31/2022	17478025310	AK-FLUOR 10% SOLN; VIAL; 5mL; 12 VIALS	10/24/2022	288.00	864.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000085	Akorn Inc	12/31/2022	17478025020	AK-FLUOR 25% SOLN; VIAL; 2mL; 12 VIALS	10/24/2022	288.00	864.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000208	Almatica	03/31/2022	52427065830	Loreev XR 1 mg extended-release capsules, 30 count	03/14/2022	140.00	425.00	01/08/2034	Single Source Drug	893	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev. These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev.  These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000208	Almatica	03/31/2022	52427066330	Loreev XR 2 mg extended-release capsules, 30 coun	03/14/2022	140.00	425.00	01/08/2034	Single Source Drug	1209	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev. These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev.  These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000208	Almatica	03/31/2022	52427066730	Loreev XR 3 mg extended-release capsules, 30 coun	03/14/2022	140.00	425.00	01/08/2034	Single Source Drug	730	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev. These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev.  These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000459	AltaThera Pharmaceuticals LLC	03/31/2022	69724011210	Sotalol hydrochloride 15mg/mL 10mL Vial	01/01/2022	246.00	2734.00	04/05/2039	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=667	None
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	82120012630	10mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	40.00	75.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	82120012730	20mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	40.00	75.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	82120012830	40mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	40.00	75.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	82120012530	5mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	40.00	75.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	70661000230	Roszet 10mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	215.00	250.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	70661000330	Roszet 20mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	215.00	250.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	70661000430	Roszet 40mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	215.00	250.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000442	Althera Pharmaeuticals LLC	09/30/2022	70661000130	Roszet 5mg rosuvastatin/10mg ezetimibe bottle 30 tab	08/15/2022	215.00	250.00	05/01/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Resetting price to original price at introduction with 0% increase
Rx0000436	Amdipharm Limited	06/30/2022	59212042204	Donnatal Oral Elixir 16.2 MG/5ML	04/01/2022	38.00	450.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212042304	Donnatal Oral Elixir 16.2 MG/5ML 16.2-0.1037-0.0194-0.0065 MG/5ML, 120 ML, Bottle	04/01/2022	38.00	450.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212042316	Donnatal PB-Hyoscy-Atrop-Scopol Elix 16.2-0.1037-0.0194-0.0065 MG/5ML, 480 ML, Bottle	04/01/2022	146.00	1795.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212024255	Lanoxin Oral Tablet 125 MCG	04/01/2022	125.00	1565.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212024256	Lanoxin Oral Tablet 125 MCG, 100 Each, Unit-Dose, Box	04/01/2022	125.00	1565.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212024955	Lanoxin Oral Tablet 250 MCG	04/01/2022	125.00	1565.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212024055	Lanoxin Oral Tablet 62.5 MCG	04/01/2022	125.00	1565.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212042216	PB-Hyoscy-Atrop-Scopol Elix 16.2-0.1037-0.0194-0.0065 MG/5ML, 480 ML, Bottle	04/01/2022	146.00	1795.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	09/30/2022	59212056210	Plaquenil Oral Tablet 200 MG	07/01/2022	106.48	1210.00	03/30/1968	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212068010	Zonegran Oral Capsule 100 MG	04/01/2022	174.00	2020.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2022	59212068110	Zonegran Oral Capsule 25 MG	04/01/2022	133.00	1560.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000231	American Health Packaging	03/31/2022	68001031356	AZACITIDINE POWDER 100MG SINGLE DOSE VIAL	01/01/2022	27.39	311.28	None	Non-innovator Multiple Source Drug	26154	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=589, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=601	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	68001050454	AZACITIDINE POWDER INJ 100MG SINGLE DOSE VIAL	01/01/2022	27.39	311.28	None	Non-innovator Multiple Source Drug	5184	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=590, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=602	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2022	68084069701	BUPROPION HCL ER (SR) TABLET 100MG 100UD	04/01/2022	8.82	80.00	None	Non-innovator Multiple Source Drug	2184	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	60687042321	CLOBAZAM TABS 10MG 30UD C4	02/01/2022	13.00	78.00	None	Non-innovator Multiple Source Drug	3174	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=600, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=612	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	68001044327	CYCLOPHOSPHAMIDE 1GM x 50ML STERILE POWDER SINGLE DOSE VIAL	01/01/2022	73.25	732.50	None	Non-innovator Multiple Source Drug	2533	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=591, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=603	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	68001044226	CYCLOPHOSPHAMIDE 500MG x 25ML STERILE POWDER, SINGLE DOSE VIAL	01/01/2022	36.62	366.25	None	Non-innovator Multiple Source Drug	2543	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=593, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=605	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	68001044432	CYCLOPHOSPHAMIDE VL 2GM x 100ML STERILE POWDER, SINGLE DOSE VIAL	01/01/2022	146.50	1465.00	None	Non-innovator Multiple Source Drug	481	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=592, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=604	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2022	62584015901	DEMECLOCYCLINE HCL TABLET 150MG 100UD	04/01/2022	63.05	693.51	None	Non-innovator Multiple Source Drug	297	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2022	60687019501	DILTIAZEM HCI CAPSULE ER 24H 120MG 100UD	07/05/2022	35.80	80.55	None	Non-innovator Multiple Source Drug	5172	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	60687019501	DILTIAZEM HCL ER CAP	02/01/2022	11.75	44.75	None	Non-innovator Multiple Source Drug	5784	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=596, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=608	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	68001034836	GEMCITABINE INJ 1GM/10ML 100MG/ML MULTIPLE DOSE VIALS-dose vials	01/01/2022	18.54	55.44	None	Non-innovator Multiple Source Drug	18360	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=594, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=606	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	68001035937	GEMCITABINE INJ 2GM/20ML 100MG/ML MULTIPLE DOSE VIALS	01/01/2022	23.53	105.60	None	Non-innovator Multiple Source Drug	3928	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=595, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=607	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2022	60687022901	LOPERAMIDE HCL CAPSULE 2MG 100UD	07/05/2022	17.94	85.00	None	Non-innovator Multiple Source Drug	9240	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2022	60687040825	MESALAMINE DR TABLET 800MG 30UD	08/30/2022	95.90	410.00	None	Non-innovator Multiple Source Drug	672	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	62584081201	OXAZEPAM CAP 10mg 10x10	02/01/2022	39.75	238.50	None	Non-innovator Multiple Source Drug	300	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=597, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=609	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	62584081301	OXAZEPAM CAP 15mg 10x10	02/01/2022	43.75	262.48	None	Non-innovator Multiple Source Drug	542	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=598, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=610	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2022	62584081401	OXAZEPAM CAP 30mg 10x10	02/01/2022	48.56	291.36	None	Non-innovator Multiple Source Drug	130	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=599, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=611	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2022	68084084401	VENLAFAXINE TABLET 37.5MG 100UD	04/01/2022	18.24	85.78	None	Non-innovator Multiple Source Drug	2412	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2022	68084085601	VENLAFAXINE TABLET 75MG 100UD	04/01/2022	19.90	93.59	None	Non-innovator Multiple Source Drug	1848	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2022	60687049301	VERAPAMIL HCL ER TABLET 120MG 100UD	04/01/2022	29.94	140.82	None	Non-innovator Multiple Source Drug	480	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2022	60687050401	VERAPAMIL HCL ER TABLET 180MG 100UD	04/01/2022	32.06	150.81	None	Non-innovator Multiple Source Drug	616	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000128	American Regent	03/31/2022	00517250210	Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk	02/01/2022	9.20	240.10	None	Non-innovator Multiple Source Drug	9037	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	Caffeine & Sodium Benzoate is not an acquired product.
Rx0000128	American Regent	06/30/2022	00517250210	Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk	06/30/2022	17.40	257.50	None	Non-innovator Multiple Source Drug	9037	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	Caffeine & Sodium Benzoate is not an acquired product.
Rx0000128	American Regent	06/30/2022	00517970225	DROPERIDOL, 2.5MG/ML, 2ML SDV, PKG. OF 25	06/27/2022	10.25	215.25	None	Non-innovator Multiple Source Drug	25765	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	Droperidol is not an acquired product.
Rx0000128	American Regent	06/30/2022	00517042001	ESTRADIOL VALERATE INJ., USP 100MG/5ML, (20 MG/ML)	06/27/2022	5.35	139.07	None	Non-innovator Multiple Source Drug	125119	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	06/30/2022	00517044001	ESTRADIOL VALERATE INJECTION, USP 200 MG /5 ML, (40 MG/ML)	06/27/2022	8.87	230.72	None	Non-innovator Multiple Source Drug	44451	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	06/30/2022	00517420125	HYDROXYZINE HCL, 25MG/ML, 1ML SDV, PKG. OF 25	06/27/2022	27.75	580.50	None	Non-innovator Multiple Source Drug	6056	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	Hydroxyzine HCL is not an acquired product.
Rx0000128	American Regent	06/30/2022	00517560125	HYDROXYZINE HCL, 50MG/ML, 1ML SDV, PKG. OF 25	06/27/2022	30.50	640.25	None	Non-innovator Multiple Source Drug	8953	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	Hydroxyzine HCL is not an acquired product.
Rx0000128	American Regent	12/31/2022	00517065001	INJECTAFER, 750MG IRON, 15ml, Pkg 1	10/03/2022	37.36	1282.71	None	Single Source Drug	658485	None	American Regent’s US Standards of Business Conduct (available at https://americanregent.com/media/3206/us-sobc-ver-10-01102022.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	There was no change or improvement.	None	None	None	None	None	None	None	None	None	None	None	We provide the following comment regarding the acquisition fields: Injectafer is not an acquired product. The licensor has granted American Regent the right to develop, manufacture, distribute and sell the product in the United States. American Regent is the NDA holder of this NDC but markets the drug through our parent company, Daiichi Sankyo, Inc.
Rx0000128	American Regent	03/31/2022	00517074020	Methylergonovine Maleate Inj., 0.2MG/ML, 1ML VL, 20 PK	02/01/2022	22.60	586.60	None	Non-innovator Multiple Source Drug	24144	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	Methylergonovine Maleate is not an acquired product.
Rx0000128	American Regent	03/31/2022	00517037405	ProvayBlue (Methylene Blue Injection), 50mg/10ml (5mg/ml), PKG OF 5	02/01/2022	112.30	1302.15	None	Single Source Drug	434640	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	American Regent does not hold any patents for the drug ProvayBlue that is the subject of the report and therefore has left the patent expiration data element blank. ProvayBlue is not an acquired product.
Rx0000128	American Regent	03/31/2022	00517231005	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 10ML, PKG. OF 5	02/01/2022	27.50	577.50	None	Single Source Drug	839845	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. Venofer is not an acquired product.
Rx0000128	American Regent	03/31/2022	00517232510	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 2.5ML, PKG. OF 10	02/01/2022	13.59	286.30	None	Single Source Drug	104030	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. Venofer is not an acquired product.
Rx0000128	American Regent	03/31/2022	00517234010	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 5ML, PKG. OF 10	02/01/2022	27.50	577.50	None	Single Source Drug	3949570	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. Venofer is not an acquired product.
Rx0000128	American Regent	03/31/2022	00517234025	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 5ML, PKG. OF 25	02/01/2022	68.75	1443.75	None	Single Source Drug	1283900	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. Venofer is not an acquired product.
Rx0000069	Amgen	03/31/2022	55513084301	Aimovig, 140 mg/mL single-dose prefilled SureClick autoinjector	01/26/2022	37.69	676.46	04/22/2036	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513084301	Aimovig, 140 mg/mL single-dose prefilled SureClick autoinjector	07/01/2022	20.29	696.75	04/22/2036	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513084101	Aimovig, 70 mg/mL single-dose prefilled SureClick autoinjector	01/26/2022	37.69	676.46	04/22/2036	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513084101	Aimovig, 70 mg/mL single-dose prefilled SureClick autoinjector	07/01/2022	20.29	696.75	04/22/2036	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513016001	Blincyto, 35 mcg lyophilized vial, 1 pk	01/26/2022	250.28	4492.38	04/06/2030	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Blincyto reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513016001	Blincyto, 35 mcg lyophilized vial, 1 pk	07/01/2022	134.77	4627.15	04/06/2030	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Blincyto reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513081328	Corlanor, 5mg oral solution AMP, 28 pk	01/26/2022	13.53	242.89	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	09/30/2022	55513081328	Corlanor, 5mg oral solution AMP, 28 pk	07/01/2022	7.29	250.18	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	03/31/2022	55513080060	Corlanor, 5mg tablet, 60 pk	01/26/2022	29.00	520.49	06/12/2027	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities.
Rx0000069	Amgen	09/30/2022	55513080060	Corlanor, 5mg tablet, 60 pk	07/01/2022	15.61	536.10	06/12/2027	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities.
Rx0000069	Amgen	03/31/2022	55513081060	Corlanor, 7.5mg tablet, 60 pk	01/26/2022	29.00	520.49	06/12/2027	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities.
Rx0000069	Amgen	09/30/2022	55513081060	Corlanor, 7.5mg tablet, 60 pk	07/01/2022	15.61	536.10	06/12/2027	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities.
Rx0000069	Amgen	03/31/2022	58406004401	Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pack	01/26/2022	110.41	1602.45	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406004401	Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pack	07/01/2022	38.46	1640.91	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406004404	Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pack	01/26/2022	441.64	6409.80	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406004404	Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pack	07/01/2022	153.84	6563.64	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406003201	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pack	01/26/2022	110.41	1602.45	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406003201	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pack	07/01/2022	38.46	1640.91	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406044501	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pk	01/26/2022	110.41	1602.45	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406044501	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pk	07/01/2022	38.46	1640.91	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406003204	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack	01/26/2022	441.64	6409.80	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406003204	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack	07/01/2022	153.84	6563.64	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406044504	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pk	01/26/2022	441.64	6409.80	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406044504	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pk	07/01/2022	153.84	6563.64	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406042534	Enbrel, 25mg (1 mL), Vial (EA), 4 pack	01/26/2022	220.82	3204.90	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406042534	Enbrel, 25mg (1 mL), Vial (EA), 4 pack	07/01/2022	76.92	3281.82	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406042541	Enbrel, 25mg (1mL), Vial (EA), 1 pack	01/26/2022	55.21	801.23	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406042541	Enbrel, 25mg (1mL), Vial (EA), 1 pack	07/01/2022	19.23	820.46	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406001001	Enbrel, 25mg/0.5mL, Syringe (ML), 1 pack	01/26/2022	55.21	801.23	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406001001	Enbrel, 25mg/0.5mL, Syringe (ML), 1 pack	07/01/2022	19.23	820.46	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406001004	Enbrel, 25mg/0.5mL, Syringe (ML), 4 pack	01/26/2022	220.82	3204.90	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406001004	Enbrel, 25mg/0.5mL, Syringe (ML), 4 pack	07/01/2022	76.92	3281.82	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406005501	Enbrel, 25mg/0.5mL, Vial (EA), 1 pack	01/26/2022	55.21	801.23	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406005501	Enbrel, 25mg/0.5mL, Vial (EA), 1 pack	07/01/2022	19.23	820.46	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406005504	Enbrel, 25mg/0.5mL, Vial (EA), 4 pack	01/26/2022	220.82	3204.90	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406005504	Enbrel, 25mg/0.5mL, Vial (EA), 4 pack	07/01/2022	76.92	3281.82	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406002101	Enbrel, 50mg/mL, Syringe (ML), 1 pack	01/26/2022	110.41	1602.45	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406002101	Enbrel, 50mg/mL, Syringe (ML), 1 pack	07/01/2022	38.46	1640.91	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406043501	Enbrel, 50mg/mL, Syringe (ML), 1 pk	01/26/2022	110.41	1602.45	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406043501	Enbrel, 50mg/mL, Syringe (ML), 1 pk	07/01/2022	38.46	1640.91	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406002104	Enbrel, 50mg/mL, Syringe (ML), 4 pack	01/26/2022	441.64	6409.80	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406002104	Enbrel, 50mg/mL, Syringe (ML), 4 pack	07/01/2022	153.84	6563.64	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	58406043504	Enbrel, 50mg/mL, Syringe (ML), 4 pk	01/26/2022	441.64	6409.80	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	58406043504	Enbrel, 50mg/mL, Syringe (ML), 4 pk	07/01/2022	153.84	6563.64	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513007801	Imlygic, 106 (1 million) PFU/mL (1.0 mL) single-use vial	01/26/2022	3.24	58.10	11/23/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513007801	Imlygic, 106 (1 million) PFU/mL (1.0 mL) single-use vial	07/01/2022	1.74	59.84	11/23/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513007901	Imlygic, 108 (100 million) PFU/mL (1.0 mL) single-use vial	01/26/2022	323.64	5809.03	11/23/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513007901	Imlygic, 108 (100 million) PFU/mL (1.0 mL) single-use vial	07/01/2022	174.27	5983.30	11/23/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	76075010301	Kyprolis, 10 mg (2mg/mL) lyophilized vial, 1 pk	01/26/2022	25.36	455.21	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	76075010301	Kyprolis, 10 mg (2mg/mL) lyophilized vial, 1 pk	07/01/2022	13.66	468.87	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	76075010201	Kyprolis, 30 mg (2mg/mL) lyophilized vial, 1 pk	01/26/2022	76.08	1365.64	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	76075010201	Kyprolis, 30 mg (2mg/mL) lyophilized vial, 1 pk	07/01/2022	40.97	1406.61	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	76075010101	Kyprolis, 60 mg lyophilized vial, 1 pk	01/26/2022	152.17	2731.28	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	76075010101	Kyprolis, 60 mg lyophilized vial, 1 pk	07/01/2022	81.94	2813.22	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513022301	Nplate, 125 mcg, 0.25mL (500 mcg/mL) single-use vial	01/26/2022	60.91	1093.26	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513022301	Nplate, 125 mcg, 0.25mL (500 mcg/mL) single-use vial	07/01/2022	32.80	1126.06	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513022101	Nplate, 250 mcg, 0.5mL (500 mcg/mL) single-use vial	01/26/2022	121.82	2186.50	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513022101	Nplate, 250 mcg, 0.5mL (500 mcg/mL) single-use vial	07/01/2022	65.60	2252.09	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513022201	Nplate, 500 mcg, 1.0mL (500 mcg/mL) single-use vial	01/26/2022	243.63	4372.99	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513022201	Nplate, 500 mcg, 1.0mL (500 mcg/mL) single-use vial	07/01/2022	131.19	4504.18	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	59572063255	Otezla, 10mg (4)-20mg (4)-30g (47) Tablet Dose Pack 55 pack	01/26/2022	292.30	4242.36	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2015	1875.00	None	This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513036955	Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack	01/26/2022	292.30	4242.36	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513036955	Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack	07/01/2022	101.82	4344.18	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	59572063255	Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pk	07/01/2022	101.82	4344.18	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2015	1875.00	None	This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513013760	Otezla, 30mg, Tablet, 60 pack	01/26/2022	292.30	4242.36	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513013760	Otezla, 30mg, Tablet, 60 pack	07/01/2022	101.82	4344.18	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	59572063106	Otezla, 30mg, Tablet, 60 pk	01/26/2022	292.30	4242.36	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2014	1875.00	None	This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	59572063106	Otezla, 30mg, Tablet, 60 pk	07/01/2022	101.82	4344.18	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2014	1875.00	None	This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513071001	Prolia, 60 mg, 1.0mL (60 mg/mL) prefilled syringe	01/26/2022	79.90	1434.14	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Prolia reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2022	55513071001	Prolia, 60 mg, 1.0mL (60 mg/mL) prefilled syringe	07/01/2022	43.02	1477.16	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Prolia reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2022	55513095401	Vectibix, 100 mg, 5 mL (20 mg/mL) single-use vial	01/26/2022	80.16	1438.85	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	09/30/2022	55513095401	Vectibix, 100 mg, 5 mL (20 mg/mL) single-use vial	07/01/2022	43.17	1482.02	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	03/31/2022	55513095601	Vectibix, 400 mg, 20 mL (20 mg/mL) single-use vial	01/26/2022	320.65	5755.40	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	09/30/2022	55513095601	Vectibix, 400 mg, 20 mL (20 mg/mL) single-use vial	07/01/2022	172.66	5928.06	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	09/30/2022	55513073001	Xgeva, 120 mg /1.7 mL (70 mg/mL) single-use vial	07/01/2022	79.14	2717.15	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Xgeva reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000122	Amneal Pharmaceuticals	09/30/2022	53746066901	Acebutolol HCl Oral Capsule 200 MG 100	07/17/2022	12.93	77.93	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	09/30/2022	53746067001	Acebutolol HCl Oral Capsule 400 MG 100	07/17/2022	17.11	103.11	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896066930	Emverm Oral Tablet Chewable 100 MG 1	02/01/2022	50.63	562.01	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	405.53	369.00	2017	369.00	None	None
Rx0000122	Amneal Pharmaceuticals	12/31/2022	65162011511	Hydrocodone Bitartrate & Acetaminophen 7.5mg-325mg Tablets 1000	12/24/2022	90.00	210.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	65162011550	Hydrocodone Bitartrate & Acetaminophen 7.5mg-325mg Tablets 500	12/24/2022	45.00	105.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	00115148701	Mixed Amphetamine Sulfate Extended Release 10mg Capsules 100	12/24/2022	41.61	116.61	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	00115148801	Mixed Amphetamine Sulfate Extended Release 15mg Capsules 100	12/24/2022	41.61	116.61	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	00115148901	Mixed Amphetamine Sulfate Extended Release 20mg Capsules 100	12/24/2022	41.61	116.61	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	00115149001	Mixed Amphetamine Sulfate Extended Release 25mg Capsules 100	12/24/2022	41.61	116.61	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	00115149101	Mixed Amphetamine Sulfate Extended Release 30mg Capsules 100	12/24/2022	41.61	116.61	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	00115148601	Mixed Amphetamine Sulfate Extended Release 5mg Capsules 100	12/24/2022	41.61	116.61	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846030115	Nizatidine Oral Solution 15 MG/ML 480	02/01/2022	55.18	612.59	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	Gemini	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	419.59	419.59	2018	419.59	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069701	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG 100	02/01/2022	116.06	699.27	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	381.56	381.56	2013	278.45	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069713	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG 60	02/01/2022	69.64	419.57	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	228.94	228.94	2013	167.07	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069801	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG 100	02/01/2022	160.94	969.69	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	529.13	529.13	2013	386.15	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069813	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG 60	02/01/2022	96.57	581.83	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	317.48	317.48	2013	231.69	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069901	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG 100	02/01/2022	205.84	1240.22	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	676.74	676.74	2013	493.86	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069913	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG 60	02/01/2022	123.51	744.14	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	406.05	406.05	2013	296.32	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896070001	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG 100	02/01/2022	296.28	1785.10	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	974.06	974.06	2013	710.84	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896070013	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG 60	02/01/2022	177.77	1071.07	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	584.44	584.44	2013	426.50	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896070101	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG 100	02/01/2022	386.71	2329.99	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	1271.39	1271.39	2013	927.82	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896070113	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG 60	02/01/2022	232.03	1398.00	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	762.84	762.84	2013	556.69	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069501	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG 100	02/01/2022	60.44	364.16	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	198.71	198.71	2013	145.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069513	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG 60	02/01/2022	36.26	218.48	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	119.22	119.22	2013	87.01	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069601	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG 100	02/01/2022	88.24	531.68	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	290.12	290.12	2013	211.72	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896069613	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG 60	02/01/2022	52.95	319.01	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	174.07	174.07	2013	127.03	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896066101	Rytary Oral Capsule Extended Release 23.75-95 MG 100	02/01/2022	34.65	384.70	12/26/2028	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	291.68	258.41	2015	230.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896066201	Rytary Oral Capsule Extended Release 36.25-145 MG 100	02/01/2022	34.65	384.70	12/26/2028	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	291.68	258.41	2015	230.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896066301	Rytary Oral Capsule Extended Release 48.75-195 MG 100	02/01/2022	34.65	384.70	12/26/2028	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	291.68	258.41	2015	230.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	64896066401	Rytary Oral Capsule Extended Release 61.25-245 MG 100	02/01/2022	43.55	483.41	12/26/2028	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	366.51	324.69	2015	289.00	None	None
Rx0000122	Amneal Pharmaceuticals	12/31/2022	65162055650	Temazepam 15mg Capsules 500	12/24/2022	33.00	60.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	12/31/2022	65162055750	Temazepam 30mg Capsules 500	12/24/2022	35.35	70.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080501	Unithroid Oral Tablet 100 MCG 100	02/01/2022	33.43	371.15	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080601	Unithroid Oral Tablet 112 MCG 100	02/01/2022	33.50	371.90	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080701	Unithroid Oral Tablet 125 MCG 100	02/01/2022	33.56	372.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080801	Unithroid Oral Tablet 137 MCG 100	02/01/2022	33.59	372.91	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080901	Unithroid Oral Tablet 150 MCG 100	02/01/2022	33.62	373.21	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846081001	Unithroid Oral Tablet 175 MCG 100	02/01/2022	33.67	373.77	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846081101	Unithroid Oral Tablet 200 MCG 100	02/01/2022	33.70	374.12	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080101	Unithroid Oral Tablet 25 MCG 100	02/01/2022	33.25	369.06	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846081201	Unithroid Oral Tablet 300 MCG 100	02/01/2022	33.74	374.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080201	Unithroid Oral Tablet 50 MCG 100	02/01/2022	33.27	369.30	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080301	Unithroid Oral Tablet 75 MCG 100	02/01/2022	33.30	369.71	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2022	60846080401	Unithroid Oral Tablet 88 MCG 100	02/01/2022	33.38	370.53	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000412	Antares Pharma, Inc	03/31/2022	54436032530	Nocdurna 27.7 mcg sublingual tablets carton 30	01/01/2022	34.65	496.61	12/01/2025	Single Source Drug	5000	None	Costs due to product acquisition, supply and marketing costs	None	increased supply and demand	None	10/01/2020	Ferring Pharmaceuticals	8750000	None	None	461.96	420.00	2018	420.00	None	this was the only price increase in past 5 yrs listed in Medispan
Rx0000412	Antares Pharma, Inc	06/30/2022	54436032530	Nocdurna 27.7 mcg sublingual tablets carton 30	04/30/2022	34.65	496.61	04/13/2030	Single Source Drug	6500	None	marketing & acquisition costs	None	Increase in supply & demand	None	10/01/2020	Ferring Pharmaceuticals	17500000	None	None	461.96	461.96	2018	420.00	None	None
Rx0000412	Antares Pharma, Inc	03/31/2022	54436035030	Nocdurna 55.3 mcg sublingual tablets carton 30	01/01/2022	34.65	496.61	12/01/2025	Single Source Drug	6642	None	Costs due to product acquisition, supply and marketing costs	None	Increased supply and demand	None	10/01/2020	Ferring Pharmaceuticals	8750000	None	None	461.96	420.00	2018	420.00	None	only price increase
Rx0000412	Antares Pharma, Inc	06/30/2022	54436035030	Nocdurna 55.3 mcg sublingual tablets carton 30	04/30/2022	34.65	496.61	04/13/2030	Single Source Drug	8000	None	marketing & acquisition costs	None	Increase in supply & demand	None	10/01/2020	Ferring Pharmaceuticals	17500000	None	None	461.96	461.96	2018	420.00	None	None
Rx0000412	Antares Pharma, Inc	12/31/2022	54436011220	TLANDO (Testosterone Undecanoate) 112.5 mg. Capsules; 120 Capsules per bottle; dosing - 2 capsules B.I.D.	12/02/2022	48.65	743.65	04/28/2041	Single Source Drug	5000	None	Increased supply and distribution costs	None	Improved marketing of product	None	03/28/2022	Lipocine	21000000	None	None	695.00	0.00	2022	695.00	None	None
Rx0000271	Apotex Corp	12/31/2022	60505437703	PAXIL CR FCT 12.5MG 30BTL USA	10/28/2022	23.70	263.12	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505437803	PAXIL CR FCT 25MG 30BTL USA	10/28/2022	24.74	274.56	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505437903	PAXIL CR FCT 37.5MG 30BTL USA	10/28/2022	25.48	282.83	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505451703	PAXIL FCT 10MG 30BTL USA	10/28/2022	23.01	255.46	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505451803	PAXIL FCT 20MG 30BTL USA	10/28/2022	24.01	266.53	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505451903	PAXIL FCT 30MG 30BTL USA	10/28/2022	24.74	274.61	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505452003	PAXIL FCT 40MG 30BTL USA	10/28/2022	26.13	290.08	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2022	60505040205	PAXIL O/SUSP 10MG/5ML 250ML BTL USA1	10/28/2022	39.94	443.46	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000435	Aquestive Therapeutics	03/31/2022	10094021060	Sympazan Oral Film 10 MG	01/03/2022	256.80	1816.80	04/03/2024	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including but not limited to clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, and overall research and development costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000435	Aquestive Therapeutics	03/31/2022	10094022060	Sympazan Oral Film 20 MG	01/03/2022	513.60	3633.60	04/03/2024	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including but not limited to clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, and overall research and development costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000435	Aquestive Therapeutics	03/31/2022	10094020560	Sympazan Oral Film 5 MG	01/03/2022	128.40	908.40	04/03/2024	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including but not limited to clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, and overall research and development costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	12/31/2022	24338001009	Bidil - Hydralazine Hydrochloride; Isosorbide Dinitrate 37.5mg;20mg Oral Tablet 90ct	10/01/2022	35.54	390.92	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	12/31/2022	24338012603	Ery-Tab Delayed Release Oral Tablet (Erythromycin) 500mg 30ct	10/01/2022	54.76	396.98	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000075	Assertio Therapeutics, Inc.	03/31/2022	13913001203	Cambia (diclofenac potassium) 50MG Oral 9 Packets	02/01/2022	64.94	886.97	06/16/2026	Single Source Drug	None	1	"Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. "	None	NONE	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past five years.
Rx0000075	Assertio Therapeutics, Inc.	03/31/2022	13913000812	Zipsor (diclofenac potassium) 25MG Oral Capsule 120 Ct Bottle	02/01/2022	136.36	1862.39	02/24/2029	Single Source Drug	None	1	"Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. "	None	NONE	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past five years.
Rx0000058	Avanir Pharmaceuiticals	03/31/2022	64597030160	Nuedexta Oral Capsule 20-10 mg Bottles of 60 Capsules	01/01/2022	90.00	1425.00	08/13/2026	Single Source Drug	None	1	Avanir is committed to making responsible pricing determinations, and in so doing we consider a range of factors. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Avanir are made at the executive level in adherence with all federal and state laws.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	The reason for the blank acquisition-related fields is that Neudexta was not acquired.
Rx0000277	Avion Pharmaceuticals, LLC	03/31/2022	75854060228	Balcoltra Oral Tablet 0.1-20 MG-MCG(21)	02/19/2022	20.03	245.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Product not acquired within last five years
Rx0000277	Avion Pharmaceuticals, LLC	03/31/2022	75854060203	Balcoltra Oral Tablet 0.1-20 MG-MCG(21)1/17/2022	01/17/2022	60.07	734.99	06/01/2027	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Columns were left blank because this product was not acquired within the last 5 years.
Rx0000108	AvKare	12/31/2022	42291096218	Estradiol Vaginal Insert 10mcg Tab - 18ct	10/05/2022	20.95	140.67	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000108	AvKare	12/31/2022	42291096208	Estradiol Vaginal Insert 10mcg Tab - 8ct	10/05/2022	9.12	62.81	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000108	AvKare	12/31/2022	42291049530	Lidocaine Patches 5% - 30ct	11/15/2022	12.74	55.57	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	06/30/2022	65628008003	FIRST Lansoprazole 3mg/mL 3 oz Suspension Compounding Kit	05/01/2022	30.00	115.00	None	Single Source Drug	3584220	None	Supply chain and market competition	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	06/30/2022	65628008005	FIRST Lansoprazole 3mg/mL 5 oz Suspension Compounding Kit	05/01/2022	20.00	115.00	None	Single Source Drug	2890560	None	Supply chain and market competition	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	12/31/2022	65628008010	FIRST Lansoprazole Powder 10 oz 300mL 3mg/mL Oral Suspension	10/01/2022	20.00	135.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	12/31/2022	65628008003	FIRST Lansoprazole Powder 3 oz 90mL 3mg/mL Oral Suspension	10/01/2022	20.00	135.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	12/31/2022	65628008005	FIRST Lansoprazole Powder 5 oz 150mL 3mg/mL Oral Suspension	10/01/2022	20.00	135.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	12/31/2022	65628007010	FIRST Omeprazole 10 oz 300ml Suspension Kit 2mg/mL	10/01/2022	20.00	135.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	06/30/2022	65628007003	FIRST Omeprazole 2mg/ml 3 oz Suspension Compounding Kit	05/01/2022	30.00	115.00	None	Single Source Drug	7507200	None	Supply chain and market competition	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	06/30/2022	65628007005	FIRST Omeprazole 2mg/ml 5 oz Suspension Compounding Kit	05/01/2022	20.00	115.00	None	Single Source Drug	7225260	None	Supply chain and market competition	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	12/31/2022	65628007003	FIRST Omeprazole 3 oz 90ML Suspension Kit	10/01/2022	20.00	135.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	12/31/2022	65628007005	FIRST Omeprazole 5 oz 150mL Suspension Kit 2mg/mL	10/01/2022	20.00	135.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None